biotech / news / / Reuters
The drugmaker achieved total sales of $14.45 billion for the first quarter.
Pfizer's first quarter sales reached $14.45 billion, exceeding analysts' expectations of $13.79 billion.
KEY POINTS
- Pfizer acquired clinical-stage obesity drugmaker Metsera for $10 billion to expand its weight-loss pipeline.
- Recent settlement of Vyndamax patent disputes with generics will delay market entry of cheaper copies.
- Pfizer reaffirmed its 2026 profit and revenue guidance despite declining COVID product sales.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →